The Updated Status and Future Direction of Immunotherapy Targeting B7-H1/PD-1 in Osteosarcoma

References

• Ni L, Dong C. New B7 family checkpoints in human cancers. Mol Cancer Ther. 2017;16(7):1203–1211. doi:10.1158/1535-7163.MCT-16-076128679835
   PubMed Web of Science ®Google Scholar
• Capece D, Verzella D, Fischietti M, et al. New B7 family checkpoints in human cancers. molecular cancer therapeutics. J Biomed Biotechnol. 2012;2012(2):926321. doi:10.1155/2012/92632122500111
   PubMedGoogle Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–477. doi:10.1038/nri232618500231
   PubMed Web of Science ®Google Scholar
• S P B, M S B, Bai A, et al. Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 t cells. J Immunol. 2012;189(4):1708–1716. doi:10.4049/jimmunol.120127122798683
   PubMed Web of Science ®Google Scholar
• Chen S, G A C, Pritchard TS, et al. Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer. 2019;7(1):305. doi:10.1186/s40425-019-0770-231730010
   PubMed Web of Science ®Google Scholar
• Masugi Y, Nishihara R, Hamada T, et al. Tumor PDCD1LG2 (PD-L2) expression and the lymphocytic reaction to colorectal cancer. Cancer Immunol Res. 2017;5(11):1046. doi:10.1158/2326-6066.CIR-17-012229038297
   PubMed Web of Science ®Google Scholar
• Lee YH, Martin-Orozco N, Zheng P, et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017;27(8):1034–1045. doi:10.1038/cr.2017.9028685773
   PubMed Web of Science ®Google Scholar
• Chen Q, Wang J, Chen W, et al. B7-H5/CD 28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma. Cancer Sci. 2019;110(2):530–539. doi:10.1111/cas.1391430548441
   PubMed Web of Science ®Google Scholar
• Chen Y, Mo J, Jia X, et al. The B7 family member B7-H6: a new bane of tumor. Pathol Oncol Res. 2018;24(4):717–721. doi:10.1007/s12253-017-0357-529086181
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Supplementary pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028. doi:10.1056/NEJMoa150182425891174
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–952. doi:10.1016/S1470-2045(18)30351-629875066
   PubMed Web of Science ®Google Scholar
• A G D, Ulahannan SV, MakorovaRusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66(3):545–551. doi:10.1016/j.jhep.2016.10.02927816492
   PubMed Web of Science ®Google Scholar
• Mcneel DG, Smith HA, J C E, et al. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother. 2012;61(7):1137–1147. doi:10.1007/s00262-011-1193-122210552
   PubMed Web of Science ®Google Scholar
• Eid JE, Garcia CB. Reprogramming of mesenchymal stem cells by oncogenes. Semin Cancer Biol. 2015;32:18–31. doi:10.1016/j.semcancer.2014.05.00524938913
   PubMed Web of Science ®Google Scholar
• Lye KL, Nordin N, Vidyadaran S, et al. Mesenchymal stem cells: from stem cells to sarcomas. Cell Biol Int. 2016;40(6):610–618. doi:10.1002/cbin.1060326992453
   PubMed Web of Science ®Google Scholar
• ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):113–123. doi:10.1093/annonc/mdu256
   Web of Science ®Google Scholar
• Ognjanovic S, Olivier M, Bergemann TL, et al. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer. 2012;118(5):1387–1396. doi:10.1002/cncr.2639021837677
   PubMed Web of Science ®Google Scholar
• Jaffe N, O S B, Bielack S. Osteosarcoma lung metastases detection and principles of multimodal therapy In: Cancer Treatment and Research Pediatric and Adolescent Osteosarcoma. Vol. 152 2010:165–184.
   Google Scholar
• Wang Y, Deng X, Yu C. Synergistic inhibitory effects of capsaicin combined with cisplatin on human osteosarcoma in culture and in xenografts. J Exp Clin Cancer Res. 2018;37(1):251. doi:10.1186/s13046-018-0922-030326933
   PubMed Web of Science ®Google Scholar
• Torabi A, Amaya CN, Wians FH Jr, et al. PD-1 and PD-L1 expression in bone and soft tissue sarcomas. Pathology. 2017;49(5):506–513. doi:10.1016/j.pathol.2017.05.00328688724
   PubMed Web of Science ®Google Scholar
• Machado I, López-Guerrero JA, Scotlandi K, et al. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8±tumor-infiltrating lymphocytes in Ewing’s sarcoma family of tumors (ESFT). Virchows Arch. 2018;472(5):815–824. doi:10.1007/s00428-018-2316-229445891
   PubMed Web of Science ®Google Scholar
• Kostine M, Cleven AH, de Miranda NF, et al. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol. 2016;29(9):1028–1037. doi:10.1038/modpathol.2016.10827312065
   PubMed Web of Science ®Google Scholar
• Koirala P, Roth ME, Gill J, et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep. 2016;6(1):30093. doi:10.1038/srep3009327456063
   PubMed Web of Science ®Google Scholar
• Zheng B, Ren T, Huang Y, et al. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol. 2018;11(1):16. doi:10.1186/s13045-018-0560-129409495
   PubMed Web of Science ®Google Scholar
• Rotz SJ, Leino D, Szabo S, et al. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer. 2017;64(12):Dec. doi:10.1002/pbc.26642
   Web of Science ®Google Scholar
• McCaughan GJ, Fulham MJ, Mahar A, et al. Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. J Hematol Oncol. 2016;9(1):48. doi:10.1186/s13045-016-0278-x27259563
   PubMed Web of Science ®Google Scholar
• Takenaka W, Takahashi Y, Tamari K, et al. Radiation dose escalation is crucial in anti-CTLA-4 antibody therapy to enhance local and distant antitumor effect in murine osteosarcoma. Cancers (Basel). 2020;12(6):1546. doi:10.3390/cancers12061546
   PubMed Web of Science ®Google Scholar
• Toda Y, Kohashi K, Yamada Y, et al. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions. J Cancer Res Clin Oncol. 2020;146(10):1–14.31724069
   PubMed Web of Science ®Google Scholar
• Liu X, He S, Wu H, et al. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo. Environ Health Prev Med. 2019;24(1). doi:10.1186/s12199-019-0835-3.
   Web of Science ®Google Scholar
• A L C, Marec-Berard P, J Y B, et al. Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. Eur J Cancer. 2019;119:151–157. doi:10.1016/j.ejca.2019.07.01831442817
   PubMed Web of Science ®Google Scholar
• Xie L, Xu J, Sun X, et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Cancer. 2020;8(1):e000798. doi:10.1136/jitc-2020-00079832376724
   PubMed Web of Science ®Google Scholar
• Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365–1369. doi:10.1038/7093210581077
   PubMed Web of Science ®Google Scholar
• Ding Q, Lu L, Zhou X, Zhou Y, Chou K-Y. Human PD-L1-overexpressing porcine vascular endothelial cells induce functionally suppressive human CD4±CD25hiFoxp3± treg cells. J Leukoc Biol. 2011;90(1):77–86. doi:10.1189/jlb.121069121498584
   PubMed Web of Science ®Google Scholar
• Krempski J, Karyampudi L, M D B, et al. Tumor-infiltrating programmed death receptor-1±dendritic cells mediate immune suppression in ovarian cancer. J Immunol. 2011;186(12):6905–6913. doi:10.4049/jimmunol.110027421551365
   PubMed Web of Science ®Google Scholar
• Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56(5):739–745. doi:10.1007/s00262-006-0272-117195077
   PubMed Web of Science ®Google Scholar
• Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–3895. doi:10.1002/j.1460-2075.1992.tb05481.x1396582
   PubMed Web of Science ®Google Scholar
• Saudemont A, Jouy N, Hetuin D, et al. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood. 2005;105(6):2428.15536145
   PubMed Web of Science ®Google Scholar
• Mazanet MM, Hughes CCW. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol. 2002;169(7):3581–3588. doi:10.4049/jimmunol.169.7.358112244148
   PubMed Web of Science ®Google Scholar
• Conrad C, Gregorio J, Wang YH, et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(±) T-regulatory cells. Cancer Res. 2012;72(20):5240–5249. doi:10.1158/0008-5472.CAN-12-227122850422
   PubMed Web of Science ®Google Scholar
• Pulko V, Harris KJ, Liu X, et al. B7-H1 expressed by activated CD8 T cells is essential for their survival. J Immunol. 2011;187(11):5606–5614. doi:10.4049/jimmunol.100397622025548
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. doi:10.1146/annurev.immunol.26.021607.09033118173375
   PubMed Web of Science ®Google Scholar
• Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543–9553. doi:10.1128/MCB.25.21.9543-9553.200516227604
   PubMed Web of Science ®Google Scholar
• Liu P, Xiao Q, Zhou B, et al. Prognostic significance of programmed death ligand 1 expression and tumor-infiltrating lymphocytes in axial osteosarcoma. World Neurosurg. 2019;129:e240–e254. doi:10.1016/j.wneu.2019.05.12131128313
   PubMed Web of Science ®Google Scholar
• Liao Y, Chen L, Feng Y, et al. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. Oncotarget. 2017;8(18):30276–30287. doi:10.18632/oncotarget.1632628415820
   PubMedGoogle Scholar
• Sundara YT, Marie Kostine AH, Cleven G, et al. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother. 2017;66(1):119–128.27853827
   PubMed Web of Science ®Google Scholar
• Lussier DM, O’Neill L, Nieves LM. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother. 2015;38(3):96. doi:10.1097/CJI.000000000000006525751499
   PubMed Web of Science ®Google Scholar
• Yoshida K, Okamoto M, Sasaki J, et al. Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells. BMC Cancer. 2020;20(1):25. doi:10.1186/s12885-019-6499-y31914969
   PubMed Web of Science ®Google Scholar
• Keremu A, Aimaiti A, Liang Z, et al. Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines. Cancer Chemother Pharmacol. 2018;83(10):255–264. doi:10.1007/s00280-018-3721-630430228
   PubMed Web of Science ®Google Scholar
• Gao WW, Zhou JJ, Ji B, et al. Evidence of interleukin 21 reduction in osteosarcoma patients due to PD-1/PD-L1-mediated suppression of follicular helper T cell functionality. DNA Cell Biol. 2017;36(9):794–800. doi:10.1089/dna.2017.366928650673
   PubMed Web of Science ®Google Scholar
• Wu W, Jing D, Meng Z, et al. FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity. Theranostics. 2020;10(6):2859–2871. doi:10.7150/thno.4127932194840
   PubMed Web of Science ®Google Scholar
• Liu Z, Wen J, Wu C, et al. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma. Aging (Albany NY). 2020;12(2):1213–1236. doi:10.18632/aging.10267931981455
   PubMedGoogle Scholar
• Ji X, Wang E, Tian F. MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling. Biochem Biophys Res Commun. 2018;495(1):1342–1348. doi:10.1016/j.bbrc.2017.11.12029170130
   PubMed Web of Science ®Google Scholar
• Zhang J, Chou X, Zhuang M, et al. LINC00657 activates PD-L1 to promote osteosarcoma metastasis via miR-106a. J Cell Biochem. 2020;121(10):4188–4195. doi:10.1002/jcb.2957431898338
   PubMed Web of Science ®Google Scholar
• Sznol M. Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy. Cancer J. 2014;20(4):290. doi:10.1097/PPO.000000000000005625098290
   PubMed Web of Science ®Google Scholar
• Wang J, Yuan R, Song W, et al. PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: the historical perspective. J Hematol Oncol. 2017;10(1):34. doi:10.1186/s13045-017-0403-528122590
   PubMed Web of Science ®Google Scholar
• Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, Phase 1–2 trial. Lancet Oncol. 2020;21(4):541–550. doi:10.1016/S1470-2045(20)30023-132192573
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493–1501. doi:10.1016/S1470-2045(17)30624-128988646
   PubMed Web of Science ®Google Scholar
• Liming X, Hao W, Wenkang Q. Irradiation enhanced the effects of PD-1 blockade in brain metastatic osteosarcoma. J Bone Oncol. 2018;12:61–64. doi:10.1016/j.jbo.2018.05.00229992089
   PubMed Web of Science ®Google Scholar
• Wang J, Hu C, Wang J, et al. Checkpoint blockade in combination with doxorubicin augments tumor cell apoptosis in osteosarcoma. J Immunother. 2019;42(9):1.30520849
   PubMed Web of Science ®Google Scholar
• Jiang K, Li J, Zhang J, et al. SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy. Int Immunopharmacol. 2019;75:105818. doi:10.1016/j.intimp.2019.10581831437795
   PubMed Web of Science ®Google Scholar
• Markel JE, Noore J, E J E, et al. Using the spleen as an in vivo systemic immune barometer alongside osteosarcoma disease progression and immunotherapy with α-PD-L1. Sarcoma. 2018;2018:1–13. doi:10.1155/2018/8694397
   Google Scholar
• Zuch D, Giang AH, Shapovalov Y, et al. Targeting radioresistant osteosarcoma cells with parthenolide. J Cell Biochem. 2012;113(4):1282–1291. doi:10.1002/jcb.2400222109788
   PubMed Web of Science ®Google Scholar
• Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int J Mol Sci. 2014;15(1):927–943. doi:10.3390/ijms1501092724434638
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Yasui T, Tamari K, et al. Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma. PLoS One. 2017;12(12):e0189697. doi:10.1371/journal.pone.018969729253865
   PubMed Web of Science ®Google Scholar
• Hu ZI, Ho AY, McArthur HL. Combined radiation therapy and immune checkpoint blockade therapy for breast cancer. Int J Radiat Oncol Biol Phys. 2017;99(1):153–164. doi:10.1016/j.ijrobp.2017.05.02928816141
   PubMed Web of Science ®Google Scholar
• Tree AC, Jones K, Hafeez S, et al. Dose-limiting urinary toxicity with pembrolizumab combined with weekly hypofractionated radiation therapy in bladder cancer. Int J Radiat Oncol Biol Phys. 2018;101(5):1168–1171. doi:10.1016/j.ijrobp.2018.04.07030012528
   PubMed Web of Science ®Google Scholar
• Tuyaerts S, Van Nuffel AMT, Naert E, et al. PRIMMO study protocol: a Phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer. BMC Cancer. 2019;19(1):506. doi:10.1186/s12885-019-5676-331138229
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–68. doi:10.1126/science.aaa496725838374
   PubMed Web of Science ®Google Scholar
• Tsukahara T, Kawaguchi S, Torigoe T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci. 2006;97(12):1374–1380. doi:10.1111/j.1349-7006.2006.00317.x16995877
   PubMed Web of Science ®Google Scholar
• Shi X, Li X, Wang H, et al. Specific inhibition of PI3Kδ/γ enhances the efficacy of anti-PD1 against osteosarcoma cancer. J Bone Oncol. 2018;16:100206. doi:10.1016/j.jbo.2018.11.00131334002
   PubMed Web of Science ®Google Scholar
• He X, Lin H, Yuan L, et al. Combination therapy with L-arginine and α-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice. Cancer Biol Ther. 2017;18(2):94–100. doi:10.1080/15384047.2016.127613628045576
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242. doi:10.1038/nri340523470321
   PubMed Web of Science ®Google Scholar
• Wang SD, H Y L, B H L, et al. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma. Int Immunopharmacol. 2016;38:81–89. doi:10.1016/j.intimp.2016.05.01627258185
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Cacavio A, Ghesani M, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6(1):24. doi:10.1186/s13569-016-0064-028042471
   PubMedGoogle Scholar
• Lussier DM, Johnson JL, Hingorani P, et al. Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer. 2015;3(1):21. doi:10.1186/s40425-015-0067-z25992292
   PubMed Web of Science ®Google Scholar
• Shimizu T, Fuchimoto Y, Okita H, et al. A curative treatment strategy using tumor debulking surgery combined with immune checkpoint inhibitors for advanced pediatric solid tumors: an in vivo study using a murine model of osteosarcoma. J Pediatr Surg. 2018;53(12):2460–2464. doi:10.1016/j.jpedsurg.2018.08.02330266483
   PubMed Web of Science ®Google Scholar
• Shimizu T, Fuchimoto Y, Fukuda K, et al. The effect of immune checkpoint inhibitors on lung metastases of osteosarcoma. J Pediatr Surg. 2017;52(12):2047–2050. doi:10.1016/j.jpedsurg.2017.08.03028954696
   PubMed Web of Science ®Google Scholar